Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8913973 | 0.81 | MEN1 (0.54) | MAPTRECQLMEN1KMT2AGAA | |
| SCHEMBL8914198 | 0.76 | MAPT (0.63) | MAPTRECQLMEN1KMT2AGAA | |
| SCHEMBL14699912 | 0.72 | RECQL (0.50) | MAPTRECQLMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1457566 | 0.70 | MAPT (0.63) | MAPTRECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL1715078 | 0.70 | PPARA (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31346663 | 0.69 | MAPK1 (0.50) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL8914384 | 0.68 | TAS2R8 (0.51) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL13140635 | 0.68 | MEN1 (0.46) | MAPTRECQLMEN1KMT2AGAA | |
| SCHEMBL6625137 | 0.67 | GAA (0.69) | MAPTRECQLMEN1KMT2AGAA | |
| SCHEMBL8914473 | 0.67 | MEN1 (0.51) | MAPTMEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | MAPT 4681/4885RECQL 188/4885MEN1 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.